Endothelin and Tubulointerstitial Renal Disease

Bonventre, 2011, Cellular pathophysiology of ischemic acute kidney injury, J Clin Invest, 121, 4210, 10.1172/JCI45161 Bellomo, 2011, Septic acute kidney injury: the glomerular arterioles, Contrib Nephrol, 174, 98, 10.1159/000329246 Heunisch, 2014, Urinary ET-1 excretion after exposure to radio-contrast media in diabetic patients and patients with preexisting mild impaired renal function, Life Sci, 118, 440, 10.1016/j.lfs.2013.12.233 Firth, 1988, Endothelin: an important factor in acute renal failure?, Lancet, 2, 1179, 10.1016/S0140-6736(88)90243-7 Kon, 1989, Glomerular actions of endothelin in vivo, J Clin Invest, 83, 1762, 10.1172/JCI114079 López-Farré, 1991, A role for endothelin in the maintenance of post-ischaemic renal failure in the rat, J Physiol (Lond), 444, 513, 10.1113/jphysiol.1991.sp018891 Shibouta, 1990, Pathophysiological role of endothelin in acute renal failure, Life Sci, 46, 1611, 10.1016/0024-3205(90)90392-5 Wilhelm, 1999, Endothelin up-regulation and localization following renal ischemia and reperfusion, Kidney Int, 55, 1011, 10.1046/j.1523-1755.1999.0550031011.x Firth, 1992, Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression, J Clin Invest, 90, 1023, 10.1172/JCI115915 Hunley, 1997, Endothelin in ischemic acute renal failure, Curr Opin Nephrol Hypertens, 6, 394, 10.1097/00041552-199707000-00015 Mino, 1992, Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats, Eur J Pharmacol, 221, 77, 10.1016/0014-2999(92)90774-X Chan, 1994, Effect of an endothelin-receptor antagonist on ischemic acute renal failure, Am J Physiol, 266, F135 Gellai, 1994, Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat, J Clin Invest, 93, 900, 10.1172/JCI117046 Clozel, 1999, Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use, J Pharmacol Exp Ther, 290, 840 Gellai, 1995, Nonpeptide endothelin receptor antagonists. V: prevention and reversal of acute renal failure in the rat by SB 209670, J Pharmacol Exp Ther, 275, 200 Forbes, 1999, Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists, Kidney Int, 55, 198, 10.1046/j.1523-1755.1999.00253.x Forbes, 2001, Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function, Kidney Int, 59, 1333, 10.1046/j.1523-1755.2001.0590041333.x Zager, 2013, Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury, Kidney Int, 84, 703, 10.1038/ki.2013.157 Neuhofer, 2006, Role of endothelin and endothelin receptor antagonists in renal disease, Eur J Clin Invest, 36, 78, 10.1111/j.1365-2362.2006.01689.x Wilhelm, 2001, The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function, Transplantation, 71, 211, 10.1097/00007890-200101270-00007 Arfian, 2012, ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury, Biochem Biophys Res Commun, 425, 443, 10.1016/j.bbrc.2012.07.121 Abu-Saleh, 2012, Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model, Life Sci, 91, 669, 10.1016/j.lfs.2012.02.002 Sutton, 2002, Microvascular endothelial injury and dysfunction during ischemic acute renal failure, Kidney Int, 62, 1539, 10.1046/j.1523-1755.2002.00631.x Jia, 2012, Prevention of renal ischemia-reperfusion injury by short hairpin RNA of endothelin A receptor in a rat model, Exp Biol Med (Maywood), 237, 894, 10.1258/ebm.2012.011368 Au, 2014, The prevention of contrast-induced nephropathy, Ann Pharmacother, 48, 1332, 10.1177/1060028014541996 Mohammed, 2013, Contrast-induced nephropathy, Heart Views, 14, 106, 10.4103/1995-705X.125926 Heyman, 1991, Early renal medullary hypoxic injury from radiocontrast and indomethacin, Kidney Int, 40, 632, 10.1038/ki.1991.255 Brezis, 1995, Hypoxia of the renal medulla—its implications for disease, N Engl J Med, 332, 647, 10.1056/NEJM199503093321006 Heyman, 1992, Radiocontrast agents induce endothelin release in vivo and in vitro, J Am Soc Nephrol, 3, 58, 10.1681/ASN.V3158 Margulies, 1991, Radiocontrast increases plasma and urinary endothelin, J Am Soc Nephrol, 2, 1041, 10.1681/ASN.V251041 Sendeski, 2012, Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta, Am J Physiol Renal Physiol, 303, F1592, 10.1152/ajprenal.00471.2012 Cantley, 1993, Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction, Kidney Int, 44, 1217, 10.1038/ki.1993.371 Brooks, 1996, Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670, Nephron, 72, 629, 10.1159/000188951 Bird, 1996, Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors, J Am Soc Nephrol, 7, 1153, 10.1681/ASN.V781153 Pollock, 1997, Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy, Ren Fail, 19, 753, 10.3109/08860229709037215 Liss, 2003, Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia, Acta Radiol, 44, 111, 10.1258/rsmacta.44.1.111 Clark, 1997, Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans, Am J Kidney Dis, 30, 82, 10.1016/S0272-6386(97)90568-0 Fujisaki, 2003, Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function, Clin Exp Nephrol, 7, 279, 10.1007/s10157-003-0246-y Simon, 2003, The nonionic radiocontrast medium iopromide does not release endothelin-1 or activate cardiac mast cells during coronary angiography, Int Arch Allergy Immunol, 131, 53, 10.1159/000070435 Chai, 2010, Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease, Heart Vessels, 25, 138, 10.1007/s00380-009-1178-6 Murakami, 2002, Plasma endothelin, nitric oxide and atrial natriuretic peptide levels in humans after abdominal angiography, Acta Radiol, 43, 340, 10.1034/j.1600-0455.2002.430319.x Ulas, 2013, Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions, J Res Med Sci, 18, 205 Wang, 2000, Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism, Kidney Int, 57, 1675, 10.1046/j.1523-1755.2000.00012.x Seeliger, 2012, Contrast-induced kidney injury: mechanisms, risk factors, and prevention, Eur Heart J, 33, 2007, 10.1093/eurheartj/ehr494 Reichetzeder, 2014, Endothelin receptor antagonists in clinical research-lessons learned from preclinical and clinical kidney studies, Life Sci, 118, 141, 10.1016/j.lfs.2014.02.025 Pittet, 1991, Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis, Ann Surg, 213, 261, 10.1097/00000658-199103000-00014 Voerman, 1992, Plasma endothelin levels are increased during septic shock, Crit Care Med, 20, 1097, 10.1097/00003246-199208000-00005 Yamaguchi, 2006, Time-dependent expression of renal vaso-regulatory molecules in LPS-induced endotoxemia in rat, Peptides, 27, 2258, 10.1016/j.peptides.2006.03.025 Jesmin, 2014, Effects of protease activated receptor (PAR)2 blocking peptide on endothelin-1 levels in kidney tissues in endotoxemic rat mode, Life Sci, 102, 127, 10.1016/j.lfs.2014.03.013 Calzavacca, 2014, Glomerular haemodynamics, the renal sympathetic nervous system and sepsis-induced acute kidney injury, Nephrol Dial Transplant, 29, 2178, 10.1093/ndt/gfu052 Schrier, 2004, Acute renal failure and sepsis, N Engl J Med, 351, 159, 10.1056/NEJMra032401 Chvojka, 2008, Renal haemodynamic, microcirculatory, metabolic and histopathological responses to peritonitis-induced septic shock in pigs, Crit Care, 12, R164, 10.1186/cc7164 Fenhammar, 2011, Endothelin receptor A antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs, PLoS One, 6, e21534, 10.1371/journal.pone.0021534 Prowle, 2009, Renal blood flow during acute renal failure in man, Blood Purif, 28, 216, 10.1159/000230813 Brenner, 1990, Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter, Chest, 98, 170, 10.1378/chest.98.1.170 Filep, 2000, Role for endogenous endothelin in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats, Br J Pharmacol, 129, 975, 10.1038/sj.bjp.0703114 Mitaka, 1999, Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist, Crit Care Med, 27, 146, 10.1097/00003246-199901000-00043 Chin, 2002, Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock, J Pediatr Surg, 37, 482, 10.1053/jpsu.2002.30871 Nitescu, 2008, Endothelin B receptors preserve renal blood flow in a normotensive model of endotoxin-induced acute kidney dysfunction, Shock, 29, 402, 10.1097/SHK.0b013e3181454118 Fenhammar, 2008, The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock, Acta Anaesthesiol Scand, 52, 1385, 10.1111/j.1399-6576.2008.01768.x Wilson, 2004, Polycystic kidney disease, N Engl J Med, 350, 151, 10.1056/NEJMra022161 Ong, 2005, Molecular pathogenesis of ADPKD: the polycystin complex gets complex, Kidney Int, 67, 1234, 10.1111/j.1523-1755.2005.00201.x Chang, 2013, New treatments for autosomal dominant polycystic kidney disease, Br J Clin Pharmacol, 76, 524 Cornec-Le Gall, 2013, Type of PKD1 mutation influences renal outcome in ADPKD, J Am Soc Nephrol, 24, 1006, 10.1681/ASN.2012070650 Paterson, 2005, Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 16, 755, 10.1681/ASN.2004090758 Persu, 2004, Comparison between siblings and twins supports a role for modifier genes in ADPKD, Kidney Int, 66, 2132, 10.1111/j.1523-1755.2004.66003.x Torres, 2009, Autosomal dominant polycystic kidney disease: the last 3 years, Kidney Int, 76, 149, 10.1038/ki.2009.128 Ecder, 2009, Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease, Nat Rev Nephrol, 5, 221, 10.1038/nrneph.2009.13 Ong, 1996, Perspectives in endothelin research: tubulointerstitial actions of endothelins in the kidney: roles in health and disease, Nephrol Dial Transplant, 11, 251, 10.1093/oxfordjournals.ndt.a027249 Reiterová, 2007, The influence of endothelin-A receptor gene polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy, Folia Biol (Praha), 53, 134 Reiterová, 2006, Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease, Kidney Blood Press Res, 29, 182, 10.1159/000095504 Munemura, 1994, Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis, Am J Kidney Dis, 24, 561, 10.1016/S0272-6386(12)80212-5 Giusti, 1995, Plasma concentration of endothelin and arterial pressure in patients with ADPKD, Contrib Nephrol, 115, 118, 10.1159/000424407 Nakamura, 1993, Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice, J Am Soc Nephrol, 4, 1064, 10.1681/ASN.V441064 Hocher, 1998, The Endothelin system in polycystic kidneys of Han:SPRD rats, J Cardiovasc Pharmacol, 31, S342, 10.1097/00005344-199800001-00095 Ong, 2003, Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease, Nephron Exp Nephrol, 93, e80, 10.1159/000068518 Song, 2009, Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks, Hum Mol Genet, 18, 2328, 10.1093/hmg/ddp165 Schieren, 2006, Gene profiling of polycystic kidneys, Nephrol Dial Transplant, 21, 1816, 10.1093/ndt/gfl071 Schrier, 2009, Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 20, 1888, 10.1681/ASN.2008080882 Hocher, 2003, ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease, J Am Soc Nephrol, 14, 367, 10.1097/01.ASN.0000042165.63601.65 Shindo, 2002, Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1, J Mol Med, 80, 105, 10.1007/s00109-001-0284-4 Hocher, 1997, Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension, J Clin Invest, 99, 1380, 10.1172/JCI119297 Ong, 1995, An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration, Kidney Int, 48, 390, 10.1038/ki.1995.307 Ong, 1994, Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function, Exp Nephrol, 2, 134 Chang, 2006, Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models, Nephrol Dial Transplant, 21, 2078, 10.1093/ndt/gfl150 Chang, 2007, Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 18, 560, 10.1681/ASN.2006090994 Growcott, 2009, Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054, Anticancer Drugs, 20, 83, 10.1097/CAD.0b013e328320791c Hocher, 2001, Effects of endothelin receptor antagonists on the progression of diabetic nephropathy, Nephron, 87, 161, 10.1159/000045906 Ge, 2005, Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure, Am J Physiol Renal Physiol, 289, F692, 10.1152/ajprenal.00100.2005 Kohan, 2006, The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure, Curr Opin Nephrol Hypertens, 15, 34, 10.1097/01.mnh.0000186852.15889.1a Torres, 2012, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 367, 2407, 10.1056/NEJMoa1205511 Wenzel, 2009, Avosentan reduces albumin excretion in diabetics with macroalbuminuria, J Am Soc Nephrol, 20, 655, 10.1681/ASN.2008050482 Dhaun, 2009, Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease, Hypertension, 54, 113, 10.1161/HYPERTENSIONAHA.109.132670